Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data

Adagrasib/Keytruda Show Preliminary ORR Of 71%

 
• By Alaric DeArment
  
earnings report
Mirati reported its third quarter earnings, as well as closely watched combination data for its KRAS G12C inhibitor and Merck's Keytruda • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business